Dancann Pharma has obtained approval from the Danish Medicines Agency to distribute two new cannabis-based medicines, Bedrolite and Bedrobinol, as part of Denmark’s pilot program for medical cannabis. The company plans to launch these products through its subsidiary, CannGros, with an expected market introduction in June or July 2025.
Both Bedrolite and Bedrobinol are designed for inhalation using CE-certified medical vaporizers. They will be included in Denmark’s state reimbursement system, which means patients can receive up to 50% coverage of treatment costs, subject to an annual limit of DKK 20,000.
After the subsidy, patients can expect to pay around 250 Danish kroner for each 5-gram product, compared to a retail price of approximately 500 Danish kroner.
Dancann Pharma has already integrated sales projections of these new products into its financial forecasts for 2025, anticipating that their launch will positively impact sales growth.
English 
Spanish 
German 
Czech